Table 1.
Sample name | Sequencing number | Base number | Mean length | Min length | Max length | OTU number |
---|---|---|---|---|---|---|
LC50_1 | 42,937 | 18,307,612 | 426.38 | 396 | 431 | 75 |
LC50_2 | 69,410 | 29,345,651 | 422.79 | 239 | 431 | 60 |
LC50_3 | 61,768 | 26,360,631 | 426.77 | 208 | 430 | 73 |
LC20_1 | 51,206 | 21,866,811 | 427.04 | 388 | 431 | 76 |
LC20_2 | 57,234 | 24,443,441 | 427.08 | 262 | 431 | 96 |
LC20_3 | 54,896 | 23,490,334 | 427.91 | 262 | 431 | 39 |
CK_1 | 38,927 | 16,481,866 | 423.40 | 232 | 492 | 91 |
CK_2 | 34,866 | 14,846,775 | 425.82 | 200 | 441 | 104 |
CK_3 | 42,380 | 18,037,215 | 425.61 | 262 | 430 | 88 |
Total | 453,624 | 193,180,336 | 425.87 | 200 | 492 | 137 |
CK: control group; LC20: treatment group with 0.0297 mg/mL of CAR; LC50: treatment group with 1.120 mg/mL of CAR. The numbers 1–3 following the sample names represent different replicates, respectively.